Individuals Discontinuing Anti-Obesity Medications Regain Weight at a Quadrupled Rate Compared to Dieters

New research suggests that patients who discontinue popular GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who end conventional diet and exercise regimens.

Findings released in a prominent health publication points out that while obese people often shed about a fifth of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such medications need to be aware of the potential of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.

This pace of recovery means a reversion to pre-treatment mass within about a year and a half.

Analyzing Treatments

The research, which looked at dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.

The team emphasize that people who lose weight through diet and exercise generally have a more gradual weight regain—around 0.1 kg a month—after stopping.

Explaining the Rapid Rebound

Experts believe the mode of action of the jabs accounts for the amplified weight return.

The injections copy a body's own chemical called GLP-1, which controls appetite.

"Artificially providing GLP-1 levels far above than the body's typical production could lead to the system to produce less of its own natural hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating far more likely."

A Lifelong Disease?

The NHS suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.

Many experts argue that, given the high risk of relapse, the treatment might need to be long-term.

This perspective is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term character of excess weight," comparing it to managing conditions like diabetes.

User Experiences

People who have stopped the jabs describe a powerful return of hunger.

"It felt as if something that goes on and you become ravenous," described a patient.

This challenge is worsened if patients have not established permanent dietary or behavioural changes during therapy.

Significant Use

Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.

• Adoption is higher among females compared to males.
• The middle-aged age group shows the highest level of interest.
• Many obtain the drugs through private prescriptions rather than public health services.

Finally, researchers stress that while these medications are effective tools for weight loss, they are not a permanent fix and lasting health benefits hinges on combined behavioural management.